MNKD(MNKD)
MNKD
ANALYST COVERAGE18 analysts
HOLD
▲ +175.1%upside to target
L $6.00
Med $8.50consensus
H $10.00PRICE
Prev Close
3.22
Open
3.19
Day Range3.07 – 3.21
3.07
3.21
52W Range2.23 – 6.51
2.23
6.51
20% of range
VOLUME & SIZE
Avg Volume
6.8M
FUNDAMENTALS
P/E Ratio
-44.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.34
Market-like
TECHNICAL
RSI (14)
56
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$954.66M
Revenue TTM$360.78M
Net Income TTM-$23.91M
Free Cash Flow$12.72M
Gross Margin76.0%
Operating Margin3.7%
Net Margin-6.6%
Return on Equity45.6%
Return on Assets-3.2%
Debt / Equity-7.38
Current Ratio1.87
EPS TTM$-0.08
MNKD News
About
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Michael Castagna
Country
United States
Website
David ThomsonExecutive Vice President, General Counsel & Secretary
Ajay AhujaExecutive VP & Chief Medical Officer
Michael E. CastagnaChief Executive Officer & Director
Stuart A. TrossChief People & Workplace Officer
Christopher PrentissChief Financial Officer
Dominic MarascoPresident of Endocrine Business Unit
Sanjay SinghExecutive Vice President of Technical Operations